全文获取类型
收费全文 | 8416篇 |
免费 | 357篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 205篇 |
儿科学 | 174篇 |
妇产科学 | 123篇 |
基础医学 | 1723篇 |
口腔科学 | 179篇 |
临床医学 | 563篇 |
内科学 | 1275篇 |
皮肤病学 | 478篇 |
神经病学 | 833篇 |
特种医学 | 307篇 |
外科学 | 1213篇 |
综合类 | 56篇 |
一般理论 | 3篇 |
预防医学 | 380篇 |
眼科学 | 197篇 |
药学 | 611篇 |
中国医学 | 24篇 |
肿瘤学 | 448篇 |
出版年
2022年 | 61篇 |
2021年 | 99篇 |
2020年 | 97篇 |
2019年 | 95篇 |
2018年 | 118篇 |
2017年 | 103篇 |
2016年 | 117篇 |
2015年 | 144篇 |
2014年 | 189篇 |
2013年 | 229篇 |
2012年 | 379篇 |
2011年 | 412篇 |
2010年 | 274篇 |
2009年 | 239篇 |
2008年 | 400篇 |
2007年 | 435篇 |
2006年 | 404篇 |
2005年 | 429篇 |
2004年 | 387篇 |
2003年 | 354篇 |
2002年 | 397篇 |
2001年 | 88篇 |
2000年 | 89篇 |
1999年 | 110篇 |
1998年 | 99篇 |
1997年 | 106篇 |
1996年 | 76篇 |
1995年 | 60篇 |
1994年 | 64篇 |
1993年 | 56篇 |
1992年 | 62篇 |
1991年 | 47篇 |
1990年 | 45篇 |
1989年 | 43篇 |
1988年 | 47篇 |
1987年 | 51篇 |
1985年 | 56篇 |
1982年 | 42篇 |
1940年 | 44篇 |
1939年 | 58篇 |
1938年 | 54篇 |
1937年 | 43篇 |
1932年 | 49篇 |
1930年 | 50篇 |
1928年 | 58篇 |
1927年 | 48篇 |
1926年 | 49篇 |
1925年 | 45篇 |
1922年 | 42篇 |
1913年 | 49篇 |
排序方式: 共有8792条查询结果,搜索用时 15 毫秒
61.
Rudolf Kadatz Walter Kobinger Alexander Walland 《Naunyn-Schmiedeberg's archives of pharmacology》1976,292(2):97-103
Summary 2,2-[(4,8-bis(diethylamino)-pyrimido [5,4-d]-pyrimidine-2,6-diyl)di-(2-methoxyethyl)imino]diethanol), RA 642, combines hypertensive and vasodilating effects. In anaesthetized animals arterial blood pressure was increased by i.v. doses of 0.25–4 mg/kg in cats and 0.025–0.25 mg/kg in dogs. In conscious dogs, 25 mm increase of mean blood pressure was achieved with 0.2 mg/kg i.v. and 18.8 mg/kg p.o. Cerebral blood flow was enhanced and calculated cerebral vascular resistance was reduced by RA 642. Total peripheral resistance was diminished by 0.25–1.0 mg/kg i.v. A vasodilatation of femoral and coronary vessels was shown after intraarterial injection. This effect as well as a BaCl2-antagonism in the isolation ileum is explained by a papaverine-like relaxant effect on smooth muscle. Activity on peripheral adrenergic receptors was excluded. Hypertension was abolished in spinalized cats, indicating a central mechanism of this effect. 相似文献
62.
Pellet JB Haefliger JA Staple JK Widmann C Welker E Hirling H Bonny C Nicod P Catsicas S Waeber G Riederer BM 《The European journal of neuroscience》2000,12(2):621-632
Islet-brain 1 (IB1) was recently identified as a DNA-binding protein of the GLUT2 gene promoter. The mouse IB1 is the rat and human homologue of the Jun-interacting protein 1 (JIP-1) which has been recognized as a key player in the regulation of c-Jun amino-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) pathways. JIP-1 is involved in the control of apoptosis and may play a role in brain development and aging. Here, IB1 was studied in adult and developing mouse brain tissue by in situ hybridization, Northern and Western blot analysis at cellular and subcellular levels, as well as by immunocytochemistry in brain sections and cell cultures. IB1 expression was localized in the synaptic regions of the olfactory bulb, retina, cerebral and cerebellar cortex and hippocampus in the adult mouse brain. IB1 was also detected in a restricted number of axons, as in the mossy fibres from dentate gyrus in the hippocampus, and was found in soma, dendrites and axons of cerebellar Purkinje cells. After birth, IB1 expression peaks at postnatal day 15. IB1 was located in axonal and dendritic growth cones in primary telencephalon cells. By biochemical and subcellular fractionation of neuronal cells, IB1 was detected both in the cytosolic and membrane fractions. Taken together with previous data, the restricted neuronal expression of IB1 in developing and adult brain and its prominent localization in synapses suggest that the protein may be critical for cell signalling in developing and mature nerve terminals. 相似文献
63.
In this, the first of two articles discussing literature for and about children, we will be considering how writing for the young has changed, reflecting different and evolving perspectives on childhood. In the second article we will be asking whether literature can be used creatively and usefully in the training of doctors. The suggestion for the topic arose from a session we organised for paediatricians in the Communication and Management module of the MSc in Child Health at Leeds University. 相似文献
64.
65.
Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. 总被引:4,自引:0,他引:4
Viviane Hess Marc Salzberg Markus Borner Rudolf Morant Arnaud D Roth Christian Ludwig Richard Herrmann 《Journal of clinical oncology》2003,21(1):66-68
PURPOSE: Preclinical studies indicate positive interactions between capecitabine, an oral fluorouracil precursor, and gemcitabine, the current standard treatment for advanced pancreatic carcinoma (APC). In this study, we investigated the addition of capecitabine to gemcitabine treatment for patients with APC. PATIENTS AND METHODS: This multicenter study included patients na?ve to chemotherapy who had histologically or cytologically confirmed, nonresectable or metastatic pancreatic carcinoma. Gemcitabine was given at a fixed dose of 1,000 mg/m(2) on days 1 and 8 of a 21-day cycle. Capecitabine was given in increasing doses orally bid for 14 days followed by a 1-week rest. The maximum-tolerated dose (MTD) was defined as one dose level below the dose causing dose-limiting toxicity (DLT) in >or= one third of a cohort of six patients. We included an additional 15 patients at the MTD. RESULTS: Thirty-six patients were included. DLT occurred at a dose of 800 mg/m(2) bid of capecitabine and consisted of myelotoxicity and mucositis. Hand-foot syndrome was not observed, and other toxic effects were mild. Thus, in this regimen, the recommended dose of capecitabine is 650 mg/m(2) bid. In 27 patients with measurable disease, we observed one complete and four partial remissions. In addition, significant drops (> 50% from baseline value) of the tumor marker CA 19-9 occurred in 14 of 24 assessable patients. CONCLUSION: The combination of capecitabine and gemcitabine is well tolerated, with apparent efficacy in patients with APC. Therefore, it is currently being compared with gemcitabine monotherapy in a phase III study. 相似文献
66.
Toshifumi Ozaki Silke Flege Matthias Kevric Norbert Lindner Rainer Maas Günter Delling Rudolf Schwarz Arthur R von Hochstetter Mechthild Salzer-Kuntschik Wolfgang E Berdel Heribert Jürgens G Ulrich Exner Peter Reichardt Regine Mayer-Steinacker Volker Ewerbeck Rainer Kotz Winfried Winkelmann Stefan S Bielack 《Journal of clinical oncology》2003,21(2):334-341
PURPOSE: To define patients and tumor characteristics as well as therapy results, patients with pelvic osteosarcoma who were registered in the Cooperative Osteosarcoma Study Group (COSS) were analyzed. PATIENTS AND METHODS: Sixty-seven patients with a high-grade pelvic osteosarcoma were eligible for this analysis. Fifteen patients had primary metastases. All patients received chemotherapy according to COSS protocols. Thirty-eight patients underwent limb-sparing surgery, 12 patients underwent hemipelvectomy, and 17 patients did not undergo definitive surgery. Eleven patients received irradiation to the primary tumor site: four postoperatively and seven as the only form of local therapy. RESULTS: Local failure occurred in 47 of all 67 patients (70%) and in 31 of 50 patients (62%) who underwent definitive surgery. Five-year overall survival (OS) and progression-free survival rates were 27% and 19%, respectively. Large tumor size (P =.0137), primary metastases (P =.0001), and no or intralesional surgery (P <.0001) were poor prognostic factors. In 30 patients with no or intralesional surgery, 11 patients with radiotherapy had better OS than 19 patients without radiotherapy (P =.0033). Among the variables, primary metastasis, large tumor, no or intralesional surgery, no radiotherapy, existence of primary metastasis (relative risk [RR] = 3.456; P =.0009), surgical margin (intralesional or no surgical excision; RR = 5.619; P <.0001), and no radiotherapy (RR = 4.196; P =.0059) were independent poor prognostic factors. CONCLUSION: An operative approach with wide or marginal margins improves local control and OS. If the surgical margin is intralesional or excision is impossible, additional radiotherapy has a positive influence on prognosis. 相似文献
67.
A noninvasive system designed for patient tracking during image-guided intranasal sinus surgery is described. It is based on optical digitizing with a custom-made registration and reference system, locatable surgical instruments, and a self-localizing operating microscope. Experimental and clinical results reveal a high degree of accuracy for the system. A mean spatial error of 0.82 ± 0.31 mm was determined for repositioning of the reference system in a plastic model of the skull. For the positioning of the microscope, a mean error of 2.3 ± 0.83 mm was calculated. Measurements of repositioning accuracy in 24 patients who received surgery for various sinus diseases had a mean spatial error of 1.56 ± 0.76 mm. The 95% error interval for locating intranasal structures using the surgical instrument was 2.05 mm, and it was 4.92 mm using the microscope. These results suggest that the use of our noninvasive registration and reference system may be effective, accurate, and useful for noninvasive tracking of patient movements in computer-assisted intranasal surgery. 相似文献
68.
The relationship between dietary fat intake and risk of colorectal cancer: evidence from the combined analysis of 13 case-control studies 总被引:3,自引:0,他引:3
Geoffrey R. Howe Kristan J. Aronson Enrique Benito Roberto Castelleto Jacqueline Cornée Stephen Duffy Richard P. Gallagher José M. Iscovich Jiao Deng-ao Rudolf Kaaks Gabriel A. Kune Susan Kune Hin P. Lee Marion Lee Anthony B. Miller Ruth K. Peters John D. Potter Elio Riboli Martha L. Slattery Dimitrios Trichopoulos Albert Tuyns Anastasia Tzonou Lyndsey F. Watson Alice S. Whittemore Anna H. Wu-Williams Zheng Shu 《Cancer causes & control : CCC》1997,8(2):215-228
The objective of this study was to examine the effects of the intakeof dietary fat upon colorectal cancer risk in a combined analysis of datafrom 13 case-control studies previously conducted in populations withdiffering colorectal cancer rates and dietary practices. Original datarecords for 5,287 cases of colorectal cancer and 10,470 controls werecombined. Logistic regression analysis was used to estimate odds ratios (OR)for intakes of total energy, total fat and its components, and cholesterol.Positive associations with energy intake were observed for 11 of the 13studies. However, there was little, if any, evidence of anyenergy-independent effect of either total fat with ORs of 1.00, 0.95, 1.01,1.02, and 0.92 for quintiles of residuals of total fat intake (P trend =0.67) or for saturated fat with ORs of 1.00, 1.08, 1.06, 1.21, and 1.06 (Ptrend = 0.39). The analysis suggests that, among these case-control studies,there is no energy-independent association between dietary fat intake andrisk of colorectal cancer. It also suggests that simple substitution of fatby other sources of calories is unlikely to reduce meaningfully the risk ofcolorectal cancer. 相似文献
69.
Galina Lurie Gertraud Maskarinec Rudolf Kaaks Frank Z Stanczyk Lo?c Le Marchand 《Cancer epidemiology, biomarkers & prevention》2005,14(6):1521-1527
There is evidence that circulating estrogens are associated with breast cancer risk. In this study of premenopausal women, we explored the association of polymorphisms in genes in the estrogen synthesis and metabolism pathways with serum and urinary levels of estrone (E1) and estradiol (E2) and with the urinary ratio of 2-hydroxyestrone (2-OHE1)/16alpha-hydroxyestrone (16alpha-OHE1). This analysis included 220 women, who were participants in a 2-year randomized soy intervention. Blood specimens were collected in the luteal phase of the menstrual cycle an average of 4.4 times over 2 years. Overnight urinary specimens were collected on the same cycle day, only at baseline. Levels of E1, E2, 2-OHE1, and 16alpha-OHE1 were measured by enzyme immunoassays. The DNA samples were analyzed by PCR/RFLP for the COMT Val158Met, CYP1A1*2A, CYP1A1*2B, CYP1A2*1F, CYP1B1 Val432Leu, and CYP17 T27C polymorphisms. We applied mixed models to investigate the relations between genotypes and repeated serum hormone measurements and generalized linear models to assess associations between genotypes and urinary estrogen metabolites. The CYP1A2 C allele was significantly associated with lower serum E2 levels; in CC genotype carriers, serum E2 levels were 26.3% lower than in homo- and heterozygous common allele carriers combined (P = 0.01). CYP1A2*1F also affected the urinary 2-OHE1/16alpha-OHE1 ratio; carriers of the variant C allele had a markedly lower ratio than individuals with the AA genotype (1.37 versus 1.76; P = 0.002). These data suggest that CYP1A2*1F is associated with lower circulating levels of E2, and that it may be a susceptibility locus for breast cancer. 相似文献
70.
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). 总被引:4,自引:0,他引:4
Beate Kempf-Bielack Stefan S Bielack Heribert Jürgens Detlev Branscheid Wolfgang E Berdel G Ulrich Exner Ulrich G?bel Knut Helmke Gernot Jundt Hartmut Kabisch Mathias Kevric Thomas Klingebiel Rainer Kotz Rainer Maas Rudolf Schwarz Michael Semik J?rn Treuner Andreas Zoubek Kurt Winkler 《Journal of clinical oncology》2005,23(3):559-568
PURPOSE: To evaluate the impact of patient, tumor, and treatment-related factors on outcome in unselected patients with recurrent osteosarcoma. PATIENTS AND METHODS: Five hundred seventy-six consecutive patients who had achieved a first complete surgical remission (CR) during combined-modality therapy on neoadjuvant Cooperative Osteosarcoma Study Group (COSS) protocols and then developed recurrent osteosarcoma were analyzed (median time from biopsy to relapse, 1.6 years; range, 0.1 to 14.3 years). There were 501 patients with metastases, 44 with local recurrences, and 31 with both. Metastases involved lungs (469 patients), bones (90 patients), and/or other sites (54 patients). RESULTS: After a median follow-up of 1.2 years for all patients and 4.2 years for survivors, actuarial overall survival (OS) rates at 2, 5, and 10 years were 0.38, 0.23, and 0.18, respectively. Five-year OS was 0.39 for 339 patients with and 0.00 for 229 patients without a second surgical CR (P < .0001). A long time to relapse, a solitary lesion, and, in the case of pulmonary metastases, unilateral disease and the absence of pleural disruption, were of positive prognostic value in uni- and multivariate analyses, as were a second surgical CR and the use of second-line chemotherapy. Radiotherapy was associated with moderately prolonged survival in patients without a second CR. The very limited prognostic differences associated with the use of second-line chemotherapy appeared to be more pronounced with polychemotherapy. CONCLUSION: Time to relapse and tumor burden correlate with postrelapse outcome in osteosarcoma. Complete surgery is an essential component of curative second-line therapy. Chemotherapy, particularly chemotherapy with more than one agent, may contribute to limited improvements in outcome. 相似文献